AXIM Stock Overview
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AXIM Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.009 |
| Beta | 1.4 |
| 1 Month Change | -11.40% |
| 3 Month Change | -46.84% |
| 1 Year Change | -52.13% |
| 3 Year Change | -98.69% |
| 5 Year Change | -99.15% |
| Change since IPO | -83.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -31.8% | 3.4% | 1.6% |
| 1Y | -52.1% | 3.8% | 25.1% |
Return vs Industry: AXIM underperformed the US Biotechs industry which returned 3.8% over the past year.
Return vs Market: AXIM underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| AXIM volatility | |
|---|---|
| AXIM Average Weekly Movement | 21.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXIM's share price has been volatile over the past 3 months.
Volatility Over Time: AXIM's weekly volatility has increased from 16% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | John Huemoeller | www.aximbiotech.com |
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.
AXIM Biotechnologies, Inc. Fundamentals Summary
| AXIM fundamental statistics | |
|---|---|
| Market cap | US$2.81m |
| Earnings (TTM) | -US$8.06m |
| Revenue (TTM) | US$39.52k |
71.2x
P/S Ratio-0.3x
P/E RatioIs AXIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXIM income statement (TTM) | |
|---|---|
| Revenue | US$39.52k |
| Cost of Revenue | US$0 |
| Gross Profit | US$39.52k |
| Other Expenses | US$8.10m |
| Earnings | -US$8.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 100.00% |
| Net Profit Margin | -20,394.96% |
| Debt/Equity Ratio | -74.0% |
How did AXIM perform over the long term?
See historical performance and comparison